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A systematic analysis of immune responses on a population level is critical for a human immunodeficiency
virus type 1 (HIV-1) vaccine design. Our studies in Botswana on (i) molecular analysis of the HIV-1 subtype
C (HIV-1C) epidemic, (ii) frequencies of major histocompatibility complex class I HLA types, and (iii) cytotoxic
T-lymphocyte (CTL) responses in the course of natural infection allowed us to address HIV-1C-specific im-
mune responses on a population level. We analyzed the magnitude and frequency of the gamma interferon
ELISPOT-based CTL responses and translated them into normalized cumulative CTL responses. The intro-
duction of population-based cumulative CTL responses reflected both (i) essentials of the predominant virus
circulating locally in Botswana and (ii) specificities of the genetic background of the Botswana population, and
it allowed the identification of immunodominant regions across the entire HIV-1C. The most robust and
vigorous immune responses were found within the HIV-1C proteins Gag p24, Vpr, Tat, and Nef. In addition,
moderately strong responses were scattered across Gag p24, Pol reverse transcriptase and integrase, Vif, Tat,
Env gp120 and gp41, and Nef. Assuming that at least some of the immune responses are protective, these
identified immunodominant regions could be utilized in designing an HIV vaccine candidate for the population
of southern Africa. Targeting multiple immunodominant regions should improve the overall vaccine immuno-
genicity in the local population and minimize viral escape from immune recognition. Furthermore, the analysis
of HIV-1C-specific immune responses on a population level represents a comprehensive systematic approach
in HIV vaccine design and should be considered for other HIV-1 subtypes and/or different geographic areas.
Human immunodeficiency virus type 1 subtype C (HIV-1C)
has become the most prevalent subtype in the current AIDS
epidemic (32, 76) and is predicted to dominate in the coming
years (32, 76). Responsible for the largest proportion of HIV-1
infections worldwide, HIV-1C apparently accounted for 47.2%
of new HIV-1 infections in the year 2000 (76). Distinguishing
features of the HIV-1C epidemics include but are not limited
to (i) a high prevalence rate (up to 20 to 40%) in the adult
population (93, 94), (ii) higher odds of vertical transmission
(81), (iii) high viral loads (68), (iv) a high level of viral diversity
(24, 72, 95), (v) preferential CCR5 coreceptor usage (1, 19, 78,
92), and (vi) a number of unique subtype signatures across the
viral genome (39, 72, 82, 84).
Vaccine protection against pathogenic simian immunodefi-
ciency virus or simian-human immunodeficiency virus was
demonstrated in a series of experiments with nonhuman pri-
mates (reviewed in references 6, 49, and 65). The induction of
strong cytotoxic T-lymphocyte (CTL) responses that are able
to control viral replication and prevent clinical disease progres-
sion was shown to be a necessary component of successful
vaccination in a rhesus macaque model (8, 10, 12, 13, 77, 91;
T. M. Fu, W. Trigona, M.-E. Davies, Z.-Q. Zhang, D. Ca-
simiro, S. Dubey, D. C. Freed, J. Joyce, K. Grimm, W. A.
Schleif, N. L. Letvin, E. A. Emini, and J. W. Shiver, AIDS
Vaccine 2001, p. 35, 2001; J. Shiver, AIDS Vaccine 2001, p.
139, 2001). A variety of viral (5, 10, 14, 25, 34, 40, 44, 45, 64, 86,
87) and bacterial (3, 29, 37, 46, 47, 55–57, 62, 73, 80, 89, 90)
vectors expressing HIV-1 antigens were reported to elicit po-
tent HIV-1-specific CTL responses, including efficient mucosal
immunity. The role of CTLs in inducing and maintaining effi-
cient immune responses was addressed in a number of HIV-1
vaccine trials (43). However, viral escape from CTL recogni-
tion during the course of experimental infection (4, 33) or from
vaccine-generated CTL protection (11) in the rhesus macaque
model suggested a functional impairment of CTLs and high-
lighted the critical role of stimulation of both neutralizing
antibodies and cellular immune responses in achieving vaccine
protection.
Ideally, vaccine formulation should target the induction of
protective immune responses against HIV-1 and, in particular,
broadly protective CTL responses. However, correlates of im-
mune protection are still unknown, and a reliable mechanism
to distinguish and select protective immune responses is not
yet available. The ability of the immune system to focus T-cell
responses to a distinct profile of epitopes, defined here as
immunodominance (17, 98), raises interest in the protection
potency of the epitopes. Identification of immunodominant
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epitopes or epitope-rich immunodominant regions that can
stimulate a broad range of HIV-specific CTLs may offer the
best mode of protection (38) and is a legitimate approach to
vaccine design. Assuming that the overall CTL responses in the
natural course of HIV-1 infection include protective immune
responses, we attempted to identify HIV-1C-specific CTL re-
sponses across the entire viral genome on a population level.
The identification of immunodominant regions and fine
mapping of epitopes are intimate parts of preparedness for
vaccine trials, including vaccine design and development. How-
ever, within the extensive list of identified HIV-1-specific
epitopes (53), there is an obvious lack of non-B subtype
epitopes representative of the areas or populations most af-
fected by the AIDS epidemic. Despite a demonstration of
cross-clade immunity in HIV-1 infection (18, 22, 31, 63, 97), a
number of subtype-specific immune responses have been re-
ported (23, 30, 83) and warrant further studies to address the
comparative significance of cross-reactive versus clade-specific
HIV-1 immunity.
Recently we characterized virus-specific CTL responses
within four HIV-1C proteins, namely, Gag, Tat, Rev, and Nef
(70). In this study we extended screening of CTL responses to
all HIV-1C proteins in the cohort of HIV-infected but asymp-
tomatic blood donors in Botswana, a southern African country
with a high prevalence of HIV-1C infection. We focused on the
comparative analysis of the magnitude and frequency of CTL
responses in the course of natural HIV-1C infection. The main
question addressed in this study was comparative cell-medi-
ated responses across the HIV-1C proteins on the population
level. CTL responses were analyzed by using the gamma inter-
feron (IFN-) ELISPOT and overlapping synthetic peptides
that spanned all HIV-1C proteins. CTL responses were ranked
by their magnitude and frequency and were expressed as nor-
malized cumulative HIV-1C-specific CTL responses, which re-
flected both (i) the essentials of the predominant circulating
virus and (ii) specificities of the genetic background of the
Botswana population through the major histocompatibility
complex (MHC) class I restriction of CTL responses. These
identified immunodominant regions throughout HIV-1C
should be considered in the design of a vaccine for the popu-
lation of southern Africa.
MATERIALS AND METHODS
Study subjects. Sample collection was performed according to the guidelines
of the Institutional Review Boards of the Ministry of Health of Botswana and the
Harvard School of Public Health as described previously (70). Briefly, peripheral
blood mononuclear cells (PBMC) were isolated from the discarded blood units
obtained anonymously from asymptomatic donors who tested HIV seropositive
at the National Blood Transfusion Centre in Gaborone, Botswana, during the
period from February 2000 to July 2001. Details of the HIV testing and sample
selection were described previously (70). The total number of study subjects was
105. Plasma viral load data were available for 103 cases (median, 37,769 copies/
ml; range, 400 to 750,000 copies/ml). CD4 and CD8 data were available for
98 study subjects. The medians for CD4 and CD8 counts were 434 and 984, and
mean values were 451 and 1,006, respectively. As described previously (70),
samples were assigned for the ELISPOT screening of HIV-1C-specific CTL
responses based on the actual PBMC viability and availability prior to when any
relevant information, including viral load, CD4, CD8, viral sequence, or HLA
typing data, had become available. Plasma viral load, CD4 and CD8 counts, and
HLA type were determined as described previously (70).
Synthetic peptides. PBMC were screened for CTL responses in the IFN-
ELISPOT assay within HIV-1C Gag, Pol, Vif, Vpr, Tat, Rev, Vpu, Env, and Nef
by using overlapping peptides of 15 to 20 amino acids (aa) in length that
overlapped by 10 aa. Forty-nine HIV-1C Gag synthetic peptides that corre-
sponded to the sequence of isolate 96ZM651.8 (accession number AF286224)
were received from the National Institutes of Health AIDS Research and Ref-
erence Reagent Program. HIV-1C consensus amino acid sequences were gen-
erated based on the full-length genome sequences (67, 71, 72). A program,
PeptGen (21), was employed for the design of most of the synthetic peptides.
Peptides spanning variable regions were represented by two or three variants.
Peptides were commercially synthesized using 9-fluorenylmethoxy carbonyl
chemistry. The purity of peptides was established by high-pressure liquid chro-
matography and in most cases was 85%.
ELISPOT assay. HIV-1C-specific CTL responses were measured by quantifi-
cation of the IFN- release in a screening ELISPOT assay as described previ-
ously (70) with overlapping synthetic peptides representing the HIV-1C consen-
sus sequence (21), a standard method widely used in CTL epitope screening
studies. Briefly, MultiScreen 96-well membrane plates (MAIP S45; Millipore)
were coated with 100 l (0.5 g/ml in phosphate-buffered saline) of an anti-
IFN- monoclonal antibody, 1-D1K (Mabtech AB, Nacka, Sweden). Synthetic
peptides were added directly to wells at a final concentration of 10 M following
an extensive phosphate-buffered saline wash. Frozen PBMC were thawed,
washed in R10 twice, and plated into the wells at a concentration of 25,000 to
100,000 cells/well. The plates were incubated at 37°C with 5% CO2 for 20 to 40 h.
Incubation with biotinylated anti-IFN- monoclonal antibody 7-B6-1 (Mabtech
AB) and streptavidin-alkaline phosphatase conjugate (Mabtech AB) was fol-
lowed by color development with an alkaline phosphatase conjugate substrate kit
(Bio-Rad, Hercules, Calif.). IFN--producing cells were counted by direct visu-
alization or by using a stereomicroscope and were expressed as spot-forming cells
(SFC) per million PBMC. The number of specific IFN--secreting T cells was
calculated by subtracting the negative control value. The negative controls were
30 SFC per million PBMC. Only responses with a magnitude of 100 SFC per
million PBMC were considered positive responses in all screening tests, which
corresponded to 10 spots at the PBMC concentration of 100,000 per well. The
CD8 T-cell specificity of the IFN- ELISPOT-based responses to synthetic
peptides was demonstrated previously by others (41, 42) and us (70) in a series
of CD8 and CD4 depletion and enrichment experiments. Cumulative CTL re-
sponses were measured as described previously (70) by summarizing the re-
sponses of per-patient analyses. Thus, the responses were cumulative because
they represent summed immune responses, which reflect both magnitude and
frequency. Comparison of cumulative CTL responses among HIV-1C proteins
was performed by normalizing the data for the number of study subjects screened
(the cumulative CTL responses observed per particular peptide were divided by
the number of study subjects screened). Thus, the responses were normalized to
avoid influence of the number of samples tested, which allowed us to compare
and rank them between and across the viral proteins.
Amino acid diversity. To compute pairwise distances within the regions, an
alignment of the HIV-1C sequences was used (71). Amino acid distances were
calculated by the PROTDIST program with the PAM model (35, 36).
Statistical analysis. Statistical analyses and basic graphical delineations were
performed using SigmaPlot 2001 (SPSS Inc.), Splus version 6.0 (Insightful
Corp.), and Microsoft Excel 2000 (Microsoft Corp.) enhanced by the package
Analyze-it (Analyze-it Software, Ltd.). Adobe Illustrator version 8.0 software was
used for final graphical presentation. The frequency of CTL responses was
compared between HIV-1C proteins by using a chi-square test. For the samples
with a positive response, the magnitude of CTL responses was compared be-
tween HIV-1C proteins by using a Wilcoxon rank sum test. A rank-based test was
used rather than a two-sample t test because the CTL responses tended to be
skewed and nonnormal and because it appropriately accounted for the censoring
of within-well ELISPOT responses of 50 spots/well. Because CTL responses to
different proteins were measured with samples from the same individuals, the
independent-samples assumption of the chi-square and Wilcoxon tests could
potentially be violated. However, the CTL responses to a variety of synthetic
peptides that represented distinct viral proteins and expressed different amino
acid sequences were measured. Also, CTL responses were grouped into sets on
the peptide basis but not on the sample/individual basis or CTL response basis.
Therefore, CTL responses to each peptide can be considered independent sets,
and thus the tests are valid, at least approximately.
For both CTL frequency and magnitude, a total of 91 pairs of proteins were
compared. To adjust for the large number of tests, the false discovery rate
procedure was used (15), with the rate of false-positive tests controlled to less
than 5%. Therefore, of the findings identified as statistically significant, fewer
than 5% are expected to be false.
To assess whether mean pairwise diversity in an immunodominant region was
different than that in the entire corresponding protein, a modification of a
one-sample t test that accounted for nonindependence of the differences in
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pairwise distances was used. The test is a one-sample analogue of the two-sample
test introduced previously (71). Briefly, the numerator of the Z-statistic is the
average of the differences in pairwise distances between subregions and complete
regions. The denominator is the standard error of the numerator. To compute it,
with n as the number of sequences, there are m  n(n  1)/2 differences in
pairwise distances, and a calculation described in reference 71 shows that c 
m(m  1)  m(n  2)(n  3)/2 of the m(m  1) pairs of differences of pairwise
distances have positive correlation due to sharing of a common sequence. Fol-
lowing reference 71, by assuming a common correlation and estimating it by
Pearson’s correlation, r, the standard error equals the square root of [(1/m)  (c
 r/m2)] multiplied by the standard deviation calculated by using all differences
in pairwise distances. The resulting Z-statistic was compared to a standard
normal distribution to test the null hypothesis. Since many tests were conducted,
the false discovery rate procedure was used to determine the cutoff P value that
implies statistical significance. All tests were two tailed.
RESULTS
Magnitude of HIV-1C-specific CTL responses. The magni-
tude of the HIV-1C-specific CTL responses was addressed on
a population level. The CTL profiles throughout the HIV-1C
proteins are presented in Fig. 1 as a digest of individual IFN-
ELISPOT-based CTL responses to the overlapping synthetic
peptides that span the HIV-1C proteins. The corresponding
statistics are introduced in Tables 1 and 2. Figure 1 highlights
profiles, magnitudes, and densities of CTL responses across
the HIV-1C proteins. Overall, a wide range of CTL response
magnitudes was detected throughout HIV-1C, both within and
between HIV-1C proteins (Table 1). The highest magnitude
was detected within the subset of synthetic peptides straddling
the Gag p24 (mean value of 388 SFC/106 PBMC; median, 300
SFC/106 PBMC), followed by Gag p2/p7/p1/p6 (mean value of
292 SFC/106 PBMC; median, 271 SFC/106 PBMC) and Nef
(mean value of 278 SFC/106 PBMC; median, 241 SFC/106
PBMC). The lowest magnitude was in the Vpu (mean value of
142 SFC/106 PBMC; median, 122 SFC/106 PBMC). Compari-
son of the magnitudes of the CTL responses between the
HIV-1C proteins revealed a number of significant differences
(Table 2). The magnitude within Gag p24 was significantly
higher than that in any other HIV-1C protein, except for the
Gag region that corresponded to the nucleocapsid and p6
domain, in which case the difference was not statistically sig-
nificant. Nef demonstrated a higher magnitude than the Pol
(except RNase H) or Env proteins, as well as Vif and Vpr.
Differences between Nef and p17, Nef and p2/p7/p1/p6, Nef
and RNase H, Nef and Tat, or Nef and Rev were not statisti-
cally significant, indicating that CTL epitopes that originated in
these regions can induce comparable magnitudes. The average
magnitude of the HIV-1C-specific CTL responses in respond-
ers was 344 SFC/106 PBMC (95% confidence interval [CI], 310
to 378) within the entire Gag protein, 215 SFC/106 PBMC
(95% CI, 193 to 237) in Pol, and 197 SFC/106 PBMC (95% CI,
178 to 216) in Env.
The density of HIV-1C-specific CTL responses, measured as
a number of significant CTL responses normalized by both a
number of peptides and a number of samples, was addressed
(Table 1). Nef and Gag p24 demonstrated the highest density
of CTL responses (0.085 and 0.078, respectively). The lowest
density was observed within the Pol RNase H (0.010), Env
gp120 (0.023), Pol integrase (0.025), Vpu (0.030), and Pol
reverse transcriptase (RT) (0.031). A high frequency of the
top-level CTL responses (higher than 500 SFC/106 PBMC) was
observed predominantly in Gag p24 (frequency of 23.4%
among all p24 CTL responses), although Gag p2/p7/p1/p6,
Nef, and Tat also demonstrated a substantial amount of high
CTL responses (frequencies of 10.5, 7.2, and 6.6%, respective-
ly). A relatively high number of nonresponsive synthetic pep-
tides were noticed in Pol RNase H (52.9% of the peptides
used), integrase (47.4%), RT (38.6%), Env gp120 (34.6%), and
Tat (27.8%).
Frequency of HIV-1C-specific CTL responses. To address
the frequency of the HIV-1C-specific CTL responses and their
profiles, the ELISPOT-based CTL responses to each synthetic
peptide were presented in the form of the fraction of tested
samples responding to a particular peptide for all HIV-1C
proteins (Fig. 2A). The average frequency of CTL responses
across all viral proteins was relatively low (mean value, 4.3%;
95% CI, 3.8 to 4.8%; median, 3.4%). The frequency varied in
a wide range from 0 to 32%, which illuminated a dramatically
uneven distribution of CTL responses across and within the
HIV-1C proteins. The frequencies of CTL responses to a num-
ber of synthetic peptides within Gag p24, Vpr, Tat, Env gp41,
and Nef were at the level of 20%, while in two cases the
frequencies reached 32.2 and 30.4% (Gag p24 and Tat, respec-
tively).
The spectrum of frequencies of CTL responses within and
between HIV-1C proteins is presented in Fig. 2B. Table 3
highlights significant differences in the CTL frequency between
different proteins. Overall, Gag p24 and Nef demonstrated
higher frequencies, while Pol proteins, Vpu, and Env gp120
showed the lowest frequencies. The frequencies of CTL re-
sponses in Gag p24 and Nef were significantly higher than
those in Gag p17, Pol protease, Pol RT, Pol RNase H, Pol
integrase, Vif, Rev, Vpu, Env gp120, and Env gp41. The Nef
frequency was also higher than those in Gag p2/p7/p1/p6 and
Tat. Peptides spanning Pol RNase H, Pol integrase, and Env
gp120 demonstrated a significantly lower frequency of CTL
responses than any other HIV-1C protein, except for the Pol
RT and Vpu.
Cumulative HIV-1C-specific CTL responses. By combining
data on CTL magnitude and CTL frequency, we introduced
normalized cumulative CTL responses as a focal feature of the
HIV-1C-specific immune response on a population level. The
nature of normalized cumulative HIV-specific CTL responses
reflects both the viral and the host components in a local AIDS
epidemic. The predominant circulating virus in a given geo-
graphic area, Botswana in particular, was mirrored through the
synthetic peptides that were synthesized based on tangible viral
sequences analyzed recently in Botswana (66, 67, 71, 72). The
MHC class I HLA types or alleles that are common locally in
Botswana were echoed in the normalized cumulative CTL re-
sponses through the restrictive nature of the viral antigens
presented on the cell surface for recognition by CD8 T cells.
Thus, the reported normalized cumulative HIV-1C-specific
CTL responses might represent an instantaneous trait of the
population-based immune response in the current HIV-1C
epidemic in Botswana.
The profiles of normalized cumulative HIV-1C-specific CTL
responses across the viral proteins are presented in Fig. 3.
Based on the magnitude and frequency of CTL responses, the
profiles highlighted responses with both high magnitude and
high frequency. The normalized cumulative HIV-1C-specific
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FIG. 1. Magnitude of HIV-1C-specific CTL responses. The x axis of each graph was scaled according to the number of HIV-1C synthetic
peptides used for a particular viral protein, and the length of the graph does not necessarily correspond to the actual size of the viral protein
because of the differences in the lengths of the synthetic peptides. The y axis was scaled equally for each viral protein. Filled dots represent
individual HIV-1C-specific CTL responses to particular synthetic peptides. CTL responses were expressed as SFC per million PBMC (sfc/mln
pbmc). Only responses equal to or higher than 100 SFC/106 PBMC were taken into account. Open dots represent nonresponsive synthetic peptides.










CTL responses were spread out extremely unevenly both be-
tween and within viral proteins. Placed on the same scale (Fig.
3), normalized cumulative CTL responses (i) demonstrated the
relative contribution of each HIV-1C protein to the CTL re-
sponses and (ii) highlighted particular regions with high and
low levels of CTL responses across HIV-1C proteins. Gag p24
contained the highest peaks of cumulative HIV-1C-specific
CTL responses, followed by a number of relatively high peaks
in Nef and fewer peaks in RT, integrase, Vif, Vpr, Tat, gp120,
and gp41.
The normalized cumulative HIV-1C-specific CTL responses
were ranked according to their value and frequency. The lo-
cations and sequences of the top 28 synthetic peptides associ-
ated with the strongest CTL responses are shown in Table 4.
These peptides were located in Gag (five peptides, including
two pairs of overlapping peptides), Pol (five peptides), Vif (two
peptides), Vpr (one peptide), Tat (two peptides), Env (four
peptides), and Nef (nine peptides, including eight overlap-
ping). The peptides demonstrated a frequency of CTL re-
sponses higher than 10% and a value of the cumulative CTL
responses higher than 25. Eight synthetic peptides were found
to represent the uppermost CTL responses in the HIV-1C
(three in Gag, one in Vpr, one in Tat, and three in Nef; the
value of cumulative the CTL responses is above 50) (Table 4).
Ranking the cumulative CTL responses allowed us to map 6
primary and 15 secondary regions across HIV-1C proteins that
corresponded to both high magnitudes and high frequencies of
CTL responses. Two out of six primary (immunodominant)
regions (Fig. 4) were identified in Gag and corresponded to aa
171 to 190 (according to the HXB2 numbering system [54])
and 291 to 320. Both Vpr and Tat contained one primary
region that extended over aa 31 to 50 and 36 to 50, respectively.
TABLE 1. Magnitude and density of HIV-1C-specific CTL responsesa
Protein No. of syntheticpeptides
Magnitude of response (SFC/106 PBMC) Density of
responseb
Frequency of high CTL
responses (%)c
No. (%d) of nonre-
sponsive peptidesMean 	 SD Median Range
Gag p17 13 258 	 143 200 100–556 0.046 5.7 1 (7.7)
Gag p24 24 388 	 270 300 100–1,447 0.078 23.4 0
Gag p2/p7/p1/p6 14 292	 162 271 100–786 0.046 10.5 2 (14.3)
Pol protease 13 163 	 67 135 107–338 0.040 0 1 (7.7)
Pol RT 44 226 	 192 168 100–1,195 0.031 5.3 17 (38.6)
Pol RNase H 17 214 	 110 210 102–438 0.010 0 9 (52.9)
Pol integrase 38 227 	 106 190 108–672 0.025 1.6 18 (47.4)
Vif 18 223 	 122 187 104–817 0.048 2.1 1 (5.6)
Vpr 9 196 	 73 196 101–403 0.067 0 0
Tat 18 249 	 115 218 117–667 0.061 6.6 5 (27.8)
Rev 19 244 	 143 220 100–1,074 0.049 2.0 0
Vpu 11 142 	 51 122 100–269 0.030 0 2 (18.2)
Env gp120 52 180 	 115 146 100–916 0.023 2.7 18 (34.6)
Env gp41 34 213 	 117 179 101–769 0.041 3.8 6 (17.6)
Nef 30 278 	 152 241 100–1,057 0.085 7.2 0
a The magnitudes and densities were computed using samples with a positive response only.
b Density was computed as the number of CTL responses higher than 100 SFC/106 PBMC within the protein normalized by the number of peptides used and the
number of samples tested [density  number of CTL responses/(number of peptides  number of samples)].
c Percentage of responses that were equal to or higher than 500 SFC/106 PBMC out of the total number of responses within a particular viral protein.
d Percentage of peptides with no responses out of the total number of synthetic peptides within a particular viral protein.
TABLE 2. Magnitude of CTL responses: relationship between HIV-1C proteinsa
Protein



















Gag p17 0.005 0.340 0.004 0.168 0.520 0.819 0.638 0.294 0.706 0.976 0.001 0.004 0.227 0.248
Gag p24 76.0 0.093 <0.001 <0.001 0.014 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.004
Gag p2/p7/p1/p6 30.0 46.0 <0.001 0.002 0.103 0.041 0.021 0.004 0.269 0.128 <0.001 <0.001 0.003 0.774
Pol protease 46.1 140.0 101.4 0.020 0.170 <0.001 0.001 0.045 <0.001 <0.001 0.087 0.752 0.017 <0.001
Pol RT 23.6 106.4 70.2 24.2 0.769 0.051 0.179 0.630 0.003 0.010 0.001 0.022 0.687 <0.001
Pol RNase H 22.1 101.6 64.5 36.7 8.2 0.511 0.785 0.741 0.240 0.281 0.037 0.157 0.931 0.089
Pol integrase 4.5 87.7 47.0 46.5 22.7 16.2 0.652 0.374 0.207 0.341 <0.001 <0.001 0.145 0.008
Vif 9.7 93.8 57.4 43.8 16.1 5.2 6.6 0.563 0.089 0.149 <0.001 0.001 0.433 0.004
Vpr 30.5 109.5 69.1 44.7 7.4 5.3 16.4 7.5 0.026 0.048 0.004 0.025 0.965 <0.001
Tat 10.0 70.0 24.0 68.0 40.0 33.6 18.5 24.7 36.0 0.698 <0.001 <0.001 0.009 0.200
Rev 0.0 77.0 32.4 68.5 38.4 27.6 16.2 21.2 29.2 6.4 <0.001 <0.001 0.040 0.125
Vpu 61.2 157.8 119.0 13.0 39.4 51.3 61.8 56.6 58.9 84.6 82.9 0.071 <0.001 <0.001
Env gp120 43.3 132.1 96.0 3.1 20.2 27.4 44.5 37.5 30.0 60.0 62.8 16.8 0.010 <0.001
Env gp41 23.6 104.1 59.3 30.7 4.0 1.6 17.1 10.5 0.3 35.0 31.2 46.3 24.8 <0.001
Nef 25.0 53.1 7.9 88.6 58.7 50.6 37.4 44.4 56.5 19.4 25.0 105.4 80.7 54.8
a The magnitude was computed using samples with a positive response only.
b The P values from the Wilcoxon rank sum test are shown in the upper triangle. According to the false discovery rate adjustment method (see Materials and
Methods), only P values of 0.024 (in boldface) are significant. The median differences in magnitude between the proteins are shown in the Tower triangle.
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Two primary regions were also identified in Nef, at aa 82 to 96
and 122 to 141. Altogether, the identified six primary regions
spanned a region of 120 aa. Combined together (Fig. 4), 6
primary (immunodominant) and 15 secondary (subdominant)
regions extended over 426 aa: 80 aa in Gag, 96 aa in Pol, 30 aa
in Vif, 20 aa in Vpr, 30 aa in Tat, 79 aa in Env, and 91 aa in Nef.
The uneven distribution of HIV-1C-specific cumulative CTL
responses across the viral proteins might provide valuable data
for vaccine design. Regions that demonstrated relatively high
cumulative CTL responses on a population level might be of
particular interest to be included into vaccine constructs. In
contrast, localities with relatively low CTL responses or with-
out CTL responses could be irrelevant in regard to potency for
CTL induction and elicitation.
Diversity within immunodominant regions. To address di-
versity within the identified immunodominant regions, a set of
73 nonrecombinant HIV-1C genome sequences (71) was uti-
lized. Translated amino acid sequences spanning each of the
immunodominant regions were aligned, and amino acid dis-
tances within the immunodominant regions were computed.
Diversity within most of the immunodominant regions was
lower than that within the entire corresponding protein (Table
TABLE 3. Frequency of CTL responses: relationship between HIV-1C proteins
Protein



















Gag p17 0.005 0.933 0.706 0.079 <0.001 0.005 0.862 0.121 0.204 0.841 0.118 <0.001 0.663 <0.001
Gag p24 3.3 0.004 <0.001 <0.001 <0.001 <0.001 0.005 0.484 0.108 0.005 <0.001 <0.001 <0.001 0.560
Gag p2/p7/p1/p6 0.0 3.2 0.671 0.063 <0.001 0.004 0.888 0.121 0.206 0.863 0.105 <0.001 0.617 <0.001
Pol protease 0.5 3.8 0.6 0.275 <0.001 0.036 0.488 0.044 0.075 0.462 0.273 0.010 1.000 <0.001
Pol RT 1.4 4.7 1.5 0.9 <0.001 0.215 0.020 <0.001 <0.001 0.016 0.777 0.061 0.110 <0.001
Pol RNase H 3.6 6.8 3.6 3.0 2.1 0.006 <0.001 <0.001 <0.001 <0.001 0.009 0.012 <0.001 <0.001
Pol integrase 2.1 5.3 2.1 1.5 0.6 1.5 <0.001 <0.001 <0.001 <0.001 0.764 0.663 0.004 <0.001
Vif 0.3 3.0 0.2 0.8 1.7 3.8 2.3 0.160 0.277 1.000 0.058 <0.001 0.399 <0.001
Vpr 2.2 1.1 2.1 2.7 3.6 5.7 4.2 1.9 0.680 0.164 0.003 <0.001 0.017 0.245
Tat 1.5 1.8 1.5 2.0 2.9 5.0 3.5 1.2 0.7 0.284 0.004 <0.001 0.024 0.026
Rev 0.3 3.0 0.3 0.8 1.7 3.9 2.4 0.0 1.9 1.2 0.052 <0.001 0.368 <0.001
Vpu 1.7 5.0 1.8 1.2 0.3 1.8 0.3 2.0 3.9 3.2 2.1 0.512 0.180 <0.001
Env gp120 2.3 5.5 2.3 1.7 0.8 1.3 0.2 2.6 4.5 3.8 2.6 0.5 <0.001 <0.001
Env gp41 0.5 3.7 0.5 0.1 1.0 3.1 1.6 0.8 2.6 2.0 0.8 1.3 1.8 <0.001
Nef 3.9 0.6 3.9 4.4 5.3 7.5 6.0 3.6 1.7 2.4 3.6 5.7 6.2 4.4
a The P values from the chi-square test are shown in the upper triangle. According to the false discovery rate adjustment method (see Materials and Methods), only
P values of 0.027 (in boldface) are significant. The differences in frequencies between the proteins are shown in the lower triangle.
FIG. 2. (A) Frequency of HIV-1C-specific CTL responses. The x axis of each graph was scaled according to the number of HIV-1C synthetic
peptides used for a particular viral protein, and the length of the graph does not necessarily correspond to the actual size of the viral protein
because of the differences in the lengths of the synthetic peptides. The y axis was scaled equally for each viral protein. Bars represent percent
frequency for a particular synthetic peptide. n represents the number of samples tested with a particular set of synthetic peptides. PR, protease;
IN, integrase. (B) Frequency distribution of HIV-1C-specific CTL responses to the synthetic peptides representing viral proteins. The boundary
of the box closest to zero indicates the 25th percentile, a solid line within the box marks the median, a dashed line within the box shows the mean
value, and the boundary of the box farthest from zero indicates the 75th percentile. Bars below and above the boxes indicate the 10th and 90th
percentiles, respectively. Points below and above the bars indicate the 5th and 95th percentiles, respectively, when the sample size permitted these
calculations. Pro, protease; IN, integrase.
VOL. 76, 2002 IDENTIFICATION OF HIV-1C IMMUNODOMINANT REGIONS 10161
 o
n






FIG. 3. Normalized cumulative HIV-1C-specific CTL responses. The x axis of each graph was scaled according to the number of HIV-1C
synthetic peptides used for a particular viral protein, and the length of the graph does not necessarily correspond to the actual size of the viral
protein because of the differences in the lengths of the synthetic peptides. The y axis was scaled equally for each viral protein. Bars represent
normalized cumulative HIV-1C-specific CTL responses to a particular synthetic peptide across the viral genome. n represents the number of










4), and significant differences (with adjustment for multiple
tests, a P value of 0.03 implies statistical significance) were
observed in 17 out of 28 regions studied. All immunodom-
inant regions within Env and Gag were less diverse than the
corresponding entire region, most strongly for Env aa 552 to
571 (Env 552-571) (mean difference, 15.1%; 95% CI, 14.0 to
16.2%) and Env 702-721 (mean difference, 11.3%; 95% CI,
9.3 to 13.4%). In addition, three of five immunodominant
regions in Gag p24 showed significantly less diversity than
Gag p24, and five of nine immunodominant regions in Nef
showed significantly restricted diversity. Furthermore Pol
894-911, Tat 36-50, and Vif 71-90 showed significantly less
diversity. In contrast, seven immunodominant regions
showed significantly greater diversity, most notably three of
five immunodominant regions in Pol, Nef 1-16 (mean dif-
ference, 7.2%; 95% CI, 12.3 to 2.1%), Tat 16-30 (mean
FIG. 4. Immunodominant regions in HIV-1C. Immunodominant and subdominant regions in the HIV-1C genome in the context of CTL
responses are shown. The locations of immunodominant and subdominant regions are scaled to their actual position in the HIV-1C genome. For
details, see Table 4. LTR, long terminal repeat; PR, protease; IN, integrase.












Start End % P value Mean difference, %(95% CI)
Gag 161 180 EKAFSPEVIPMFTALSEGAT 10.2 47.3 3.2 0.0001 6.2 (4.8, 7.6)
171 190 MFTALSEGATPQDLNTMLNT 32.2 190.5 2.5 <0.0001 6.9 (5.5, 8.4)
291 310 EPFRDYVDRFFKTLRAEQAT 18.6 80.2 3.2 0.0062 1.9 (0.5, 3.2)
301 320 FKTLRAEQATQDVKNWMTDT 17.0 87.7 5.5 <0.0001 4.0 (2.1, 5.9)
331 350 KTILRALGPGATLEEMMTAC 15.3 43.7 7.2 0.0043 2.2 (0.7, 3.7)
Pol 271 290 FSVPLDEDFRKYTAFTIPSI 12.7 48.8 9.3 0.0064 2.8 (4.9, 0.8)
421 440 WASQIYPGIKVRQLCKLLRG 10.9 44.8 9.9 0.12 3.5 (8.0, 1.0)
521 540 KQLTEAVOKIAMESIVIWGK 10.9 27.3 11.2 0.0001 4.8 (6.8, 2.9)
894 911 AVFIHNFKRKGGIGGYSA 14.1 41.4 3.0 0.0001 3.4 (2.5, 4.4)
925 942 TKELQKQIIKIQNFRVYY 15.6 36.7 9.8 0.00025 3.4 (5.3, 1.6)
Vif 61 80 EARLVIKTYWGLOTGERDWH 12.7 32.8 18.4 0.0001 6.8 (9.5, 4.0)
71 90 GLQTGERDWHLGHGVSIEWR 16.4 41.1 9.4 0.016 2.2 (0.4, 3.9)
Vpr 31 50 VRHFPRPWLHSLGQYIYETY 21.4 52.6 19.4 <0.0001 7.5 (9.9, 5.0)
Tat 16 30 SQPKTACNKCYCKRC 10.7 25.0 31.8 0.0001 13.5 (16.5, 10.4)
36 50 VCFQTKGLGISYGRK 30.4 96.0 11.9 <0.0001 5.9 (3.9, 7.9)
Env 299 319 PNNNTRKSIRIGPGQTFYA 11.3 28.1 10.7 0.0001 9.4 (7.6, 11.1)
552 571 QSNLLRAIEAQQHMLQLTVW 10.7 25.2 4.9 0.0001 15.1 (14.0, 16.2)
702 721 LSIVNRVRQGYSPLSFQTLT 10.7 29.3 8.7 0.0001 11.3 (9.3, 13.4)
742 761 RDRSIRLVSGFLALAWDDLR 19.6 42.2 17.4 0.028 2.6 (0.3, 5.0)
Nef 1 16 MGGKWSKSSIVGWPAV 12.7 27.9 25.8 0.0059 7.2 (12.3, 2.1)
67 81 GFPVRPQVPLRPMTY 12.7 45.1 9.2 0.0001 9.4 (5.5, 13.3)
72 86 PQVPLRPMTYKGAFD 16.4 43.8 16.1 0.20 2.5 (1.3, 6.2)
77 91 RPMTYKGAFDLSFFL 12.7 35.2 20.1 0.35 0.5 (4.7, 1.6)
82 96 KGAFDLSFFLKEKGG 20.0 60.4 16.3 0.064 2.3 (0.1, 4.7)
97 111 LEGLIYSKKRQEILD 12.7 40.7 15.2 0.0095 3.4 (0.8, 6.0)
112 126 LWVYHTQGYFPDWQN 16.4 38.4 11.1 0.0001 7.5 (5.5, 9.6)
122 136 PDWQNYTPGPGVRYP 18.2 50.6 9.0 <0.0001 9.7 (7.4, 11.9)
127 141 YTPGPGVRYPLTFGW 14.5 56.9 8.5 <0.0001 10.1 (8.0, 12.2)
a The top eight immunodominant regions are in boldface.
b Cumulative CTL responses were normalized by the number of samples screened with a particular set of synthetic peptides.
c The amino acid diversity for a particular immunodominant region was compared with the amino acid diversity of the entire corresponding viral protein (P value
and mean difference).
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difference, 13.5%; 95% CI, 16.5 to 10.4%), Vif 61-80
(mean difference, 6.8%; 95% CI, 9.5 to 4.0%), and
Vpr 31-50 (mean difference, 7.5%; 95% CI, 9.9 to
5.0%).
DISCUSSION
Although the correlates of immune protection remain to be
elucidated, eliciting HIV-1-specific CD8 T-cell responses re-
mains a critical goal of vaccine design.
We have focused on the antigenic component of an HIV
vaccine and have approached strengthening of the vaccine
immunogenicity through the identification of the immune re-
sponses specific to the prevailing HIV-1 subtype on a popula-
tion level. Our goal was to identify and rank potential CTL
epitope-rich regions throughout HIV-1C that could be consid-
ered in a vaccine design. We analyzed the magnitude and
frequency of CTL responses across the viral genome as essen-
tial elements and vital characteristics of the overall cell-medi-
ated immune responses. Amplified on a population level, this
measurement of virus-specific CTL responses has become an
important attribute of the regional HIV-1C epidemic and pro-
vided an overview of the distribution and density of HIV-1C-
specific CTL responses in the Botswana population (Fig. 1, 2A,
and 3).
In this study we addressed the magnitude, frequency and
normalized cumulative HIV-1C-specific CTL responses in Bo-
tswana, a country with a very high prevalence of HIV-1C. Our
previous study provided data for the profiles of CTL responses
in four HIV-1C proteins (70), while in this study we presented
a comparative analysis and ranking of CTL responses through-
out the viral genome. The CTL responses were analyzed for
natural HIV-1 infections in asymptomatic HIV-1-infected
blood donors, a cohort that fairly represented the general
population in Botswana.
The extent to which the results of this study could be ex-
trapolated to the general population in Botswana or to the
nearby area would depend on how representative a chosen
cohort of blood donors was in relation to the general popula-
tion in the same geographic area. A comparative analysis of the
MHC class I HLA allele frequencies within the general pop-
ulation in Botswana (69) and within the blood donors (70)
revealed a similar distribution of the HLA alleles and antigen
specificities within the HLA-A, -B, and -C loci. Taken in the
context of the nature of MHC class I restriction of CD8 T-cell
responses, similarities in the HLA allele frequencies between
blood donors and the general population provided evidence
that the profiles of CTL responses and identified immunodom-
inant regions across HIV-1C might fairly represent the overall
cell-mediated immune responses in the HIV epidemic in Bo-
tswana. Moreover, the predominant virus in the local HIV-1
epidemic was represented by the HIV-1C-specific synthetic
peptides that were synthesized based on the actual sequences
from Botswana and used in the study to quantify virus-specific
CTL responses. This match provides an additional link be-
tween circulating virus and identified CTL responses in Bot-
swana. The overall HIV vaccine design and development
would benefit if a similar methodology for the analysis of
virus-specific immune responses on a population level would
be considered in other studies that target discrete HIV-1 sub-
types and/or different populations in distinct geographic areas.
We observed an uneven distribution and disproportionate
density of CTL responses in HIV-1C. An introduction of the
normalized cumulative HIV-1C-specific CTL responses al-
lowed us to identify a number of regions across HIV-1C that
were associated with an increased level of virus-specific CTL
responses in the Botswana population.
Differences in the magnitude and frequency of CTL re-
sponses between and within HIV-1C proteins highlighted the
uneven character of CTL responses across the viral genome
(Tables 1 to 3; Fig. 2B). A phenomenon of CTL epitope clus-
tering can be found within the HIV-1 proteins, namely, Gag,
Pol, Env, and Nef (20, 27, 42, 53, 99; A. Bansal, S. Sabbaj, B.
Edwards, D. Ritter, J. Tang, B. Korber, R. Kaslow, C. Wilson,
P. Goepfert, and M. Mulligan, AIDS Vaccine 2001, p. 39,
2001). Although CTL epitopes were shown to be associated
with more conserved regions in viral proteins (28, 85), no
preference for epitope clusters to be in either conserved or
variable regions was reported (100).
A profile of CTL epitope clustering might reflect specifics of
immune responses to the predominant HIV variant in a par-
ticular population. The results of our study were consistent
with the data of Goulder et al. (42), who showed that the
HIV-1C-specific CTL responses in Africans clustered within
Gag p24, while HIV-1B-specific CTL responses in Caucasians
grouped in Gag p17. In addition, profiles of HIV-1C-specific
CTL responses in this study differed from the dominant HIV-
1B-specific CTL responses in the regulatory HIV proteins Tat
and Rev (2) and in the accessory proteins Vif, Vpr, and Vpu
(7), highlighting subtype- and host-specific aspects of immune
responses in HIV-1 infection. In contrast, CTL responses in
Nef clustered in the central region of the protein in both
HIV-1C- and HIV-1B-infected cohorts (27, 61, 70; A. Bansal,
D. Ritter, S. Sabbaj, C. Perkins, B. Edwards, B. Korber, D.
Kaslow, C. Wilson, P. Goepfert, and M. Mulligan, AIDS Vac-
cine 2001, p. 39, 2001). We analyzed patterns of CTL epitope
clustering between HIV-1B and -1C by comparing the HIV-1B
data from the HIV Molecular Immunology 2000 database (53)
with the locations of HIV-1C immunodominant regions in this
study. The profiles of CTL epitopes and epitope-rich regions
within most viral proteins, except gp41 and Nef, were notice-
ably dissimilar (data not shown). Taken together, differences in
the distribution of CTL responses and a relatively unique na-
ture of CTL profiles in Botswana might suggest that CTL
responses depend on the predominant circulating virus and
genetic background of the population. This might be particu-
larly accentuated between distinct geographic areas that have a
predominance of a particular viral subtype or variant and rel-
atively homogeneous ethnicity of the population. In contrast,
an absence of clustering and a deceptively even spread of CTL
epitopes might be observed in geographic areas with multiple
HIV-1 subtypes and/or circulating recombinant forms and het-
erogeneous hosts. Whether the profiles of virus-specific CTL
responses differ between HIV-1 subtypes and/or between geo-
graphic areas and the extent of the difference are subjects for
future studies.
Although a detailed analysis of the factors that can affect
virus-specific CTL responses was beyond the scope of this
study, it is noteworthy that molecular modification and en-
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hancement might improve immunogenicity and efficiency of
vaccine constructs. For example, a deletion of 19 N-terminal
amino acids in Nef that included the myristoylation site was
shown to completely eliminate both MHC class I and CD4
down-regulation (79), which might suggest that the first sub-
dominant region in Nef (aa 1 to 16) should be omitted from the
vaccine construct. Moreover, such factors as intracellular pro-
cessing, binding affinity, and presentation efficiency of viral
antigens can influence and alter CTL responses and should be
considered in a vaccine design. The expression level of the
MHC class I-peptide complex on the cell surface and the
frequency of CTL precursors might impinge on the magnitude
of virus-specific CTL responses (38). Epitopes in a natural viral
protein might not necessarily be optimal for binding to MHC
molecules (74). The flanking residues of the CTL epitopes may
(16, 88) or may not (58) affect proper processing and recogni-
tion of the presented epitopes. Yield and availability (26, 50,
96) together with efficiency of CTL epitope processing (59) are
believed to be major determinants of immunogenicity. More-
over, the use of cytokines and costimulatory molecules can
enhance and steer CTL responses (9, 13, 48). Therefore, the
immunodominant regions identified across HIV-1C in this
study warrant further research to address coherent engineering
of vaccine constructs in order to achieve optimal processing
and immunogenicity. Fine mapping of CTL epitopes within the
identified immunodominant and subdominant regions could
further improve the design of an HIV-1C vaccine. In addition,
an extreme HIV-1 variability might hamper efficiency of im-
mune responses and CTL competence in particular. Allen et
al. reported that viral escape variants associated with muta-
tions in Tat CTL epitopes emerged during acute simian im-
munodeficiency virus infection (4). In addition, Kelleher et al.
described viral escape variants of HIV-1 Gag following the loss
of the specific CTL response to Gag and the subsequent de-
tection of partial reversion to the original wild-type sequence
(51). These findings do support our conclusion that given the
high variability of HIV, the vaccine approach of incorporating
consensus sequences rich in CTL epitopes of HIV should have
a better chance to provide a broader coverage of HIV variants
and to minimize the escape variants than those approaches
that rely on limited viral genes derived from a single variant.
Our study suggested that inclusion of the identified immu-
nodominant and subdominant regions into vaccine constructs
may improve the immunogenicity of a vaccine designed spe-
cifically for the Botswana population. Multiple immunodomi-
nant regions should minimize viral escape from immune rec-
ognition due to simultaneous targeting of several viral
proteins, even in the case when some of the immunodominant
regions could not elicit sufficient immune responses. A CTL-
based vaccine construct could include immunodominant and
subdominant regions, for example, as a DNA plasmid encod-
ing a tandem of CTL-rich regions across HIV-1C. The notion
that tandemly repeated sequences can significantly potentiate
B- and T-cell-mediated immunogenicity (52, 60, 75, 101) sug-
gests that the use of tandem arrays of immunodominant CTL
regions might be advantageous in HIV vaccine design. In con-
trast, immunologically silent regions with low magnitudes and
frequencies of CTL responses might be omitted from the vac-
cine constructs.
Recently we identified consensus sequences that might be
utilized for an AIDS vaccine design and demonstrated relative
distance for the consensus sequences that represent different
subsets of HIV-1C sequences (71). Thus, a vaccine construct
based on the consensus sequences of the identified immuno-
dominant regions in Botswana could presumably be immuno-
genic in other southern African countries, assuming a relatively
great overlap of common MHC class I HLA alleles between
ethnic groups in southern Africa. Further molecular monitor-
ing of the HIV epidemic might be required to guide additional
modifications of the vaccine constructs to correspond to the
current virus in the epidemic.
In summary, this study focused on T-cell responses in natu-
ral HIV-1C infection in Botswana, a country severely affected
by the AIDS epidemic. Comparative analysis revealed that the
magnitudes and frequencies of the HIV-1C-specific CTL re-
sponses were spread unevenly across the viral genome, within
and between most of the viral proteins. Regions with increased
magnitude and/or frequency, as well as regions with low CTL
responses or without CTL responses, were identified through-
out HIV-1C. Profiles of cumulative HIV-1C-specific immune
responses allowed us to identify and rank immunodominant
and subdominant regions within viral proteins. The strongest
CTL responses were identified within Gag p24, Vpr, Tat, and
Nef. Subdominant CTL responses were also distributed in Gag
p24, Pol RT and integrase, Vif, Tat, Env gp120 and gp41, and
Nef. The study represented a comprehensive, systematic ap-
proach for an HIV vaccine design on a population level and
suggested the inclusion of identified immunodominant regions
into vaccine constructs to restrain the HIV-1C epidemic in
Botswana.
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